Third Harmonic Bio, Inc. is a biopharmaceutical company. The Company is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The Company is advancing its lead product candidate, THB335, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway and gastrointestinal tract. THB335 is a potent, highly selective, oral small molecule KIT inhibitor with a promising preclinical product profile.
企業コードTHRD
会社名Third Harmonic Bio Inc
上場日Sep 15, 2022
最高経営責任者「CEO」- -
従業員数53
証券種類Ordinary Share
決算期末Sep 15
本社所在地1700 Montgomery Street
都市SAN FRANCISCO
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号94111
電話番号12097272457
ウェブサイトhttps://thirdharmonicbio.com/
企業コードTHRD
上場日Sep 15, 2022
最高経営責任者「CEO」- -
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし